Pre-market · Oct 6, 6:50 am ET · After hours $14.31 0.00%
Open$14.14
Prev close$14.20
Day range$13.90 – $14.34
Volume65.1K
Market cap$2.50B
P/E (TTM)178.9
Dividend yield–
HCM Stock News
Headlines matching Hutchmed (China) or the HCM ticker, most recent first.
Daiwa upgrades HUTCHMED (00013.HK) to “Buy,” raising target price to HK$28.5AASTOCKS · 4 Sep 2026
Hutchmed (China) Target Price Raised to HK$39.00 From HK$36.00 by Citi Research 0013.HKDow Jones · 4 Sep 2026
Hutchmed (00013.HK) announced that it has entered into a licensing agreement with GlaxoSmithKline for a KRAS-EGFR antibody-drug conjugate cancer therapy.Gelonghui Finance · 3 Sep 2026
Hutchmed (00013.HK) announced the submission of a New Drug Application (NDA) in the United States for the combination of ORPATHYS and TAGRISSO for the treatment of MET-driven EGFR-mutated lung cancer.Gelonghui Finance · 29 Sep 2026
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Raises Target Price to $18Market news · 21 Sep 2026
Hutchmed (0013.HK): The innovative drug segment posted a steady recovery in 1H26, with a flurry of catalysts expected in 2H26–2027; target price raised.Bank of Communications International · 3 Aug 2026
Hutchmed (00013.HK): The SAFFRON global Phase III study of savolitinib has yielded positive results, potentially accelerating its global regulatory submissions.Dongwu Securities · 18 Aug 2026
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $17Market news · 7 Jul 2026
Goldman Sachs Maintains Hutchmed (China)(HCM.US) With Hold Rating, Cuts Target Price to $14Market news · 23 Jul 2026
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $20Market news · 1 Jun 2026
Morgan Stanley Upgrades Hutchmed (China)(HCM.US) to Hold Rating, Cuts Target Price to $13.6Market news · 29 May 2026
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $21Market news · 6 Mar 2026
CICC maintains an 'Outperform Industry' rating for Hutchmed (00013) with a target price of 30 Hong Kong dollars.Zhitong Finance · 12 Mar 2026
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $20Market news · 10 Mar 2026
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $22Market news · 22 Jan 2026
Discussion
No comments yet — be the first to weigh in on HCM.
No comments yet — be the first to weigh in on HCM.